Prof. Eric Albrecht, MD, DESA’s Post

Trust the unique formulation of IN.PACT™ for precise drug delivery, ensuring a sustained anti-restenotic effect¹. See the difference in the results. https://bit.ly/3S7JfEu

ICYMI: Cornea Update: Stability and Sterility of Extemporaneously Prepared Nonpreserved Cefazolin, Ceftazidime, Vancomycin, Amphotericin B, and Methylprednisolone Eye Drops: Purpose: To determine in-use stability and sterility of fortified cefazolin, ceftazidime, vancomycin, amphotericin B, and methylprednisolone eye drops in a simulated inpatient setting with and without a mobile refrigerated container (MR). Methods: Each drug was prepared and divided into 4 groups: 1) simulated patient use with the MR group: stored at 4°C and kept in the MR during drug administration, 2) simulated patient use without the MR (NoMR) group: stored at 4°C and no MR, 3) refrigerated control group: stored at 4°C, and 4) room temperature control group: stored at room temperature. Stability and sterility data were evaluated at days 0, 4, 7, 14, 21, and 28. Linear mixed-effects model and survival analysis were performed. Results: Median time to 10% loss of concentration for in-use medications (MR/NoMR groups) was >28/27.9, 22.2/22.2, 19.4/19.4, 10.18/28/>28 days for cefazolin, ceftazidime, vancomycin, amphotericin B, and methylprednisolone, respectively. There was no significant difference in the predicted concentration loss per day among all groups for vancomycin and methylprednisolone (all P > 0.05). For the other study medications, all room temperature control groups, the cefazolin NoMR group, and the ceftazidime NoMR group had significantly greater predicted concentration loss per day compared with the refrigerated control groups (all P ≤ 0.02). Culture results were negative for all drugs throughout the study. Conclusions: The NoMR group showed that the drug significantly degraded rapidly for cefazolin, ceftazidime, and amphotericin B. Implementation of MR could decrease the predicted loss of concentration per day for cefazolin and ceftazidime. In vitro antimicrobial activity and sterility were retained for 28 days. http://dlvr.it/T15bFs #Cornea #MostPopularArticles #Ophthalmology

📰 Examine the effectiveness of enoxaparin dosing regimens in achieving anti-Xa targets for VTE prophylaxis in morbidly obese patients. Discover the impact on patient outcomes and dosing strategies. #Pharmacy #VTEProphylaxis #Enoxaparin Link: https://lnkd.in/dVDgf-aw Authors: Sabers, A. et al.

Indian Chest Society Launches Special Booklet On Cough Management The Indian Chest Society (ICS) has unveiled a special booklet titled 'Guidelines For Cough Management in India,' focusing on the comprehensive management of cough in India. The special booklet is part of ICS’ medical initiative supported by Dr. Reddy's Laboratories, a global pharmaceutical company headquartered in Hyderabad, India as a scientific partner. Through this booklet, ICS aims to illuminate the prevalence of cough, explore its diverse causes, and provide insights into its diagnosis and management. The distinguished panel of eight pulmonologists, comprising Vijai Kumar Singh, Vice President of ICS, Deepak Talwar, Honorary Secretary of ICS, DR PRADYUT WAGHRAY, Dr. Maulik Sanghvi, S Z Dr Jafrey, Dr. Mahavir Modi, Dr Meghana Subhash, and Dr. Visweswaran, has been instrumental in shaping the content of this booklet The booklet will be available on ICS’ website soon. #indianchestsociety #GuidelinesForCoughManagementinIndia #cough #drreddyslabs #drreddyslabsnews

Ophthopedia Update:Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go: To discuss the clinical trial results leading to the FDA approval of anti-complement therapies for geographic atrophy (GA), perspectives on functional data from the GA clinical trials, and how lessons from the FDA approval may guide future directions for basic and clinical research in AMD. #Ophthalmology #Ophthotwitter #Scicomm

🌟 EXPERT INSIGHTS: Alumis recently announced it has commenced patient dosing in its ONWARD phase 3 clinical program evaluating ESK-001, an oral allosteric TYK2 inhibitor, for moderate to severe plaque #psoriasis. Martin Babler, CEO of Alumis, recently discussed the significance of this clinical program and the potential of ESK-001 in the psoriasis treatment landscape. 🖇 Read more now: https://lnkd.in/g7Z_n2ib

Idiots guide on how not to design a clinical trial in patients with chronic rhinosinusits (CRS) https://lnkd.in/eBAGUfHh So you have a new exhalation delivery system (EDS) to enhance topical delivery of fulticasone propionate (FP) for the treatment of CRS with (CRSwNP) or without nasal poplys (CRSsNP) First you need to show efficacy vs placebo : Well that's a rather easy hurdle to pass imho However the key question here is surely whether EDS-FP is any better than intranasal FP delivered by conventional aqueous nasal spray (or MF/BUD ) or FP/BUD nasal drops (FP drops not available in US) at a therapeutically equivalent dose Without such data one can not properly assess the relative clinical efficacy of the new EDS-FP formulation in CRS Then in pts with CRSwNP don't bother to measure other key objective outcomes such as the endoscopic NP score or airflow obstruction with peak nasal inspiratory flow or improved ostiometal patency with nasal NO -because these don't really matter ? Oh yes and by the way don't measure systemic adverse effects such as adrenal suppression with the new EDS-FP which enhances systemic biovailability of FP as Cmax by 38% -FP incidentally has no first pass innactivation in the nose or sinuses-esepically as FP is highly lipophilic and has a long elimination half life of 14 hours , in turn resulting in a large volume of distribution and drug accumulation with repeated bid dosing Also as blood eosinophils are a key predictor of response to intranasal corticosteroid in pts with NP don't perform an informative post hoc analysis looking at response according to Eos≥300/ul vs <300/ul Finally don't employ a run-out phase on oral corticosteroid to cf with response to EDS-FP or conventional FP spray Congratulations you're now all good to go !

Ophthopedia Update:Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs: Eye, Published online: 04 March 2024; doi:10.1038/s41433-024-03001-8Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs #Ophthalmology #Eye #Ophthotwitter

Based on recent statistics, up to 14% of women experience chronic pelvic pain, which can be disabling and associated with other chronic health conditions. Only a third of those women seek medical care. We need progress in this area, pain does not need to be normal. NICHD is grateful for partnership with FDA in this area. Join this upcoming workshop to learn more! #NICHDImpact #Womenshealth #pelvicpain #endometriosis #adenomyosis #painresearch

In response to tremendous medical need and unprecedented market demand, Vivani is accelerating the development of two miniature, long-term GLP-1 implants for the treatment of obesity and chronic weight management: NPM-115 (exenatide) and NPM-139 (semaglutide).   These implants have the potential to transform and advance the adoption of GLP-1 therapy by directly addressing the limitations of currently marketed products, which include poor medication adherence and tolerability.   Read more here: https://lnkd.in/ep5tZ_fE.   #WeightLossDrugs #Semaglutide